Schrödinger (SDGR) Q4 2025 earnings review
The Growth Illusion: GAAP Revenue Drops While Cost Cuts Take Center Stage
Schrödinger's Q4 delivered a jarring optical reversal: Software revenue dropped 13% YoY, dragging total revenue down 1.2%. Management attributes this to an accelerated transition to ratable, hosted software contracts, pivoting investor attention to Annual Contract Value (ACV). However, ACV growth severely decelerated to just 4.0% for the full year, exposing underlying stagnation in customer expansion. The real bright spot is financial discipline. By abandoning independent clinical trials, OpEx fell 12.2% in Q4, and the company posted a $32.5M Net Income (aided by a $50M investment gain). Schrödinger is sacrificing near-term growth vanity for a credible path to positive Adjusted EBITDA by 2028.
🐂 Bull Case
The strategic pivot away from independent clinical development, combined with May's RIF, removed massive cost overhangs. OpEx is steadily declining, drastically reducing cash burn and cementing a realistic timeline for 2028 profitability.
While small accounts churn, Top 20 Pharma ACV grew an accelerating 15.3% YoY to $80.8M. The core thesis that large, well-capitalized enterprises will scale their adoption of physics-based AI platforms remains intact.
🐻 Bear Case
Commercial Net Dollar Retention plummeted from 113% in 2024 to a dead-flat 100% in 2025. This means existing customers effectively stopped increasing their spend—a massive red flag for a SaaS company historically valued on 'land and expand'.
The 4% total ACV growth proves the ongoing biotech funding winter is crushing smaller accounts. If new logo acquisition remains frozen, management's 10-15% ACV growth guidance for FY26 looks highly vulnerable.
⚖️ Verdict: ⚪
Neutral. The transition to ratable software contracts and disciplined cost cuts makes the business much healthier, but the sudden collapse in Net Dollar Retention fundamentally contradicts the management's narrative of broad, accelerating platform adoption.
Key Themes
Net Dollar Retention Stagnation
The most alarming data point in the release completely contradicts management's rosy narrative on 'robust customer engagement.' Net Dollar Retention for commercial customers decelerated violently from 113% in FY24 to 100% in FY25. This means upselling to existing customers only just covered churn. Total ACV grew merely 4.0% to $198.5M. The core growth engine has stalled.
The Hosted Software Revenue Shock
Q4 Software revenue collapsed 13% YoY to $69.3M. Management points to a deliberate, accelerated transition from on-premise deployments (upfront recognition) to hosted/ratable models. While strategically sound for long-term predictability, this will artificially suppress GAAP revenue growth in the short-to-medium term. Hosted revenue reached 23% of total software revenue in FY25, up from 20% in FY24.
Clinical Pivot Delivers Immediate OpEx Relief
The decision announced in Q3 to cease advancing internal discovery programs into the clinic independently is paying massive dividends. Operating expenses have been steadily decelerating, down 12.2% YoY in Q4 to $74.5M. This disciplined capital allocation is the sole reason the 2028 positive Adjusted EBITDA target holds water.
Drug Discovery Collaborations Surge
Drug discovery revenue was the unquestionable growth engine in 2025, accelerating 107% YoY to $56.4M (and up 107% in Q4 alone). This reflects execution on major partnerships, particularly the amortization of the $150M Novartis upfront payment and 16 programs now eligible for royalties.
Macro Weakness: The Biotech Winter
The stark divide between Top 20 Pharma ACV (+15.3%) and total Commercial ACV (+7.0%) exposes severe weakness in the lower and middle market. As noted in prior quarters, the macro environment for small/emerging biotech is forcing shutdowns and budget cuts, acting as a structural anchor on new customer acquisition.
Platform Evolution: RetroSynth & Manas AI
Schrödinger is aggressively defending its technical moat. In January, it launched RetroSynth (AI-driven synthesis route identification) and integrated with Lilly TuneLab to marry federated learning with physics-based simulation. A new strategic agreement with Manas AI further bolsters its algorithmic accuracy.
Other KPIs
Reversing. A significant improvement from $(152.5)M in FY24. Q4 alone improved to $(5.2)M from $(6.6)M. The combination of structural headcount reductions and shifting away from clinical trial costs is steadily shrinking the operational cash burn.
Stable. Up from $367.5M at the end of FY24. The strong balance sheet insulates Schrödinger from current capital market volatility and provides more than enough runway to execute its goal of hitting breakeven by the end of 2028 without needing dilutive equity raises.
Reversing positively. Software gross margin recovered to 81% in Q4 after dipping into the 68-73% range earlier in the year due to Gates Foundation predictive toxicology grant costs. FY25 finished at 74%. Management is guiding for a return to the 'high 70s' by 2028.
Guidance
Accelerating. Implies 10-15% growth over FY25's $198.5M. This is a highly aggressive target given that FY25 only achieved 4.0% ACV growth and NDR was flat. Achieving this will require a massive rebound in small/mid-market biotech purchasing or unprecedented expansion within Top 20 Pharma.
Decelerating. Implies roughly flat to 15% growth vs FY25's $56.4M. This compares to the massive 107% growth seen in FY25, reflecting the normalization of milestone payments and the steady amortization of existing mega-deals like Novartis.
Decelerating. Confirms the structural shift in the company's cost base. Savings from the cessation of independent clinical trials and the May 2025 headcount reductions are permanent.
Represents the trailing four-quarter basis of $197M to $201M. Given the transition to a ratable model, ACV is now the only clean metric to evaluate software velocity, though it remains heavily weighted toward the backend of the calendar year.
Key Questions
The Net Dollar Retention Disconnect
NDR fell to exactly 100% in 2025, down from 113%. With existing customers essentially pausing expansion, how do you bridge from 4% actual ACV growth in 2025 to your aggressive 10-15% ACV growth guidance for 2026?
Hosted Transition Financial Impact
You are accelerating the shift to hosted software deployments by 2028. What is the specific modeled headwind to GAAP software revenue for FY26 as upfront licenses convert to ratable?
Partnering SGR-1505 and SGR-3515
Following the strategic pivot to stop independent clinical development, what is the status of out-licensing discussions for the MALT1 and Wee1/Myt1 assets, and are upfront payments factored into the 2026 drug discovery revenue guidance?